Cover Story
Free
This series re-examines the concurrent controversies at the Cancer Prevention and Research Institute of Texas and MD Anderson Cancer Center. This examination is possible in part because of new insight provided by Alfred Gilman, the Nobel laureate who served as the first scientific director of the state institution that distributes $300 million a year. Gilman died on Dec. 23, 2015.
In Brief
Drugs & Targets
Trending Stories
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Trump 2016: A look back at the 45th president’s impact on oncology
- A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Long-term risks from prostate cancer treatment detailed in new report